FORT PIERCE, Fla. - ColoradoDesk -- Caring Brands Inc. (N A S D A Q: CABR) $CABR is advancing a differentiated consumer health strategy built around exclusive licensing, patented formulations, and clinically validated products. The company's latest milestone—securing an exclusive global license to manufacture and commercialize Emesyl, an over-the-counter nausea relief product—adds a meaningful new growth vector while reinforcing its portfolio-based approach to scale.

The Emesyl agreement positions CABR to participate in a global nausea treatment market projected to exceed $6.23 billion, while complementing its existing dermatology and hair-growth offerings and accelerating its multi-year product launch roadmap.

Exclusive Global Rights to Emesyl Unlock New Commercial Opportunity

On January 5, Caring Brands announced it entered into an exclusive worldwide license agreement with Itonis, Inc. to manufacture, market, and distribute Emesyl, an established OTC nausea relief product.

Under the agreement:

• CABR holds exclusive global commercialization rights
• CABR assumes control of manufacturing, marketing, sales strategy, and global distribution
• Itonis will provide technical data, formulation details, historical sales information, and intellectual property support
• The agreement includes royalties based on future net sales
• CABR may earn equity in Itonis, tied to defined revenue milestones

According to QY Research, the global market for nausea treatment and related therapies is projected to exceed USD $6.23 billion in 2025, highlighting the scale of the opportunity as CABR revitalizes and expands Emesyl's market presence.

More on Colorado Desk

• Custom Home Builder Connecticut Valley Homes Wins 2025 Home of the Year from the Modular Home Builders Association
• Scoop Social Co. Partners with Air Canada to Celebrate New Direct Flights to Milan with Custom Italian Piaggio Ape Gelato Carts
• Breakout Phase for Public Company: New Partnerships, Zero Debt, and $20 Million Growth Capital Position Company for 2026 Acceleration
• Japan's Patented "Hammock'n" Smartphone Band Targets Hand Fatigue From Long Phone Use
• Reditus Group Introduces A New Empirical Model for Early-Stage B2B Growth

CEO Glynn Wilson commented:

"Securing the exclusive rights to Emesyl marks an important milestone for Caring Brands as we expand our health and wellness portfolio. Emesyl brings a recognized product with real commercial potential, and we look forward to revitalizing and scaling its market presence."

Portfolio-Driven Strategy with Multiple Revenue Streams

Caring Brands is building a diversified portfolio of unique, patented, and clinically validated products, reducing reliance on any single asset while expanding its total addressable market.

Current and pipeline products include:

• Hair Enzyme Booster – for hair loss
• Photocil – for psoriasis and vitiligo
• CB-101 – in development for eczema
• NoStingz – a sunscreen designed to prevent jellyfish stings
• Emesyl – OTC nausea relief (exclusive global license)

The company is already generating revenue through:

• Direct U.S. product sales
• International licensing partners, including India

CABR plans to launch five products over the next two years, while continuing to in-license additional assets, expanding both geographic reach and category exposure.

Proven Management Execution Model

CABR's leadership team brings a track record of strategic acquisitions, rapid product development, IP creation, and licensing execution. The company's model emphasizes:

• Leveraging existing clinical validation
• Accelerating time-to-market
• Controlling branding and commercialization
• Monetizing products via both direct sales and licensing

This disciplined approach allows Caring Brands to scale efficiently while managing development risk.

More on Colorado Desk

• CCHR: Harvard Review Exposes Institutional Corruption in Global Mental Health
• ZeroDown Software Appoints Tony Wong as Vice President of Corporate Development
• Advanced LASIK & Vision Correction Now Available in Westminster With 20/20 Institute
• Goatimus Launches Dynamic Context: AI Prompt Engineering Gets Smarter
• 20/20 Institute Launches Englewood LASIK & Vision Correction Page

N A S D A Q Uplisting Strengthens Capital Markets Position

In November, Caring Brands completed a $4.0 million underwritten public offering in conjunction with its uplisting to the N A S D A Q Capital Market.

Key transaction details:

• 1,000,000 shares priced at $4.00 per share
• $4.0 million in gross proceeds
• 45-day option for underwriters to purchase up to 150,000 additional shares
• Underwriter: D. Boral Capital LLC

The proceeds are intended for:

• Marketing and sales expansion
• Working capital
• Repayment of certain debt

The Nasdaq listing enhances CABR's visibility, liquidity, and access to institutional investors as it advances multiple commercialization initiatives.

Investment Perspective

Caring Brands is positioning itself as a portfolio-driven consumer health company with multiple near-term and mid-term catalysts, including:

• Exclusive global rights to Emesyl in a $6.23B market
• Planned five product launches over the next two years
• Existing revenue from dermatology and hair-growth products
• A scalable licensing and commercialization framework
• Strengthened balance sheet following its Nasdaq uplisting

As Emesyl progresses toward global rollout and additional products come to market, CABR offers investors exposure to diversified OTC health opportunities driven by execution and disciplined expansion.

Company: Caring Brands Inc. (N A S D A Q: CABR)
Media & Investor Contact:
Brian S. John, Chief Investment Officer
Email: info@caringbrands.com
Phone: (561) 896-7616

Website: www.caringbrands.com

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website